- Член од
- 16 јули 2021
- Мислења
- 1.080
- Поени од реакции
- 1.937
Pfizer major products:
Prevnar 13, a pneumococcal conjugate vaccine, had $5.9 billion in 2020 revenues; Ibrance (palbociclib) for treatment of breast cancer, had $5.4 billion in 2020 revenues; Eliquis (apixaban) to treat and prevent venous thrombosis and to prevent stroke in people with nonvalvular atrial fibrillation, had $4.9 billion in 2020 revenues; Xeljanz (tofacitinib) to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, had $2.4 billion in 2020 revenues; Enbrel (etanercept) to treat autoimmune diseases, had $1.4 billion in 2020 revenues; Xtandi (enzalutamide) to treat prostate cancer, had $1.0 billion in 2020 revenues; and Vyndaqel/Vyndamax (tafamidis) to treat familial amyloid polyneuropathy, had $1.3 billion in 2020 revenues. Other high-revenue products by Pfizer include Chantix/Champix (varenicline) to treat nicotine addiction, had $919 million in 2020 revenues; Inlyta (axitinib), a tyrosine kinase inhibitor to inhibit growth of breast cancer, had $787 million in 2020 revenues; Nimenrix, a meningococcal vaccine, had $221 million in 2020 revenues; FSME/IMMUN-TicoVac, a tick-borne encephalitis vaccine, had $196 million in 2020 revenues; Genotropin, a growth hormone therapy, had $427 million in 2020 revenues; Somavert (pegvisomant), a growth hormone receptor antagonist used in the treatment of acromegaly, had $277 million in 2020 revenues; Toviaz (fesoterodine), an antimuscarinic drug to treat overactive bladders, had $252 million in 2020 revenues; Bone morphogenetic protein 2, had $274 million in 2020 revenues; Sutent (sunitinib), used to treat cancer, had $819 million in 2020 revenues; Xalkori (crizotinib), an anaplastic lymphoma kinase and c-ros oncogene 1 inhibitor for treatment of non-small cell lung carcinoma, had $544 million in 2020 revenues; Bosulif (bosutinib), a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia, had $450 million in 2020 revenues; Retacrit, an erythropoiesis-stimulating agent, had $386 million in 2020 revenues; Lorbrena (lorlatinib), an anaplastic lymphoma kinase and c-ros oncogene 1 inhibitor used for the treatment of non-small-cell lung cancer, had $204 million in 2020 revenues; Sulperazon (cefoperazone/sulbactam), an antibiotic used for the treatment of urinary tract infections, had $618 million in 2020 revenues; Medrol (methylprednisolone), a glucocorticoid, had $402 million in 2020 revenues; and Vfend (voriconazole), an antifungal medication, had $270 million in 2020 revenues.[1]
П.С. Им се може lycku vis a vis помадата и марамиците на браќава
Prevnar 13, a pneumococcal conjugate vaccine, had $5.9 billion in 2020 revenues; Ibrance (palbociclib) for treatment of breast cancer, had $5.4 billion in 2020 revenues; Eliquis (apixaban) to treat and prevent venous thrombosis and to prevent stroke in people with nonvalvular atrial fibrillation, had $4.9 billion in 2020 revenues; Xeljanz (tofacitinib) to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, had $2.4 billion in 2020 revenues; Enbrel (etanercept) to treat autoimmune diseases, had $1.4 billion in 2020 revenues; Xtandi (enzalutamide) to treat prostate cancer, had $1.0 billion in 2020 revenues; and Vyndaqel/Vyndamax (tafamidis) to treat familial amyloid polyneuropathy, had $1.3 billion in 2020 revenues. Other high-revenue products by Pfizer include Chantix/Champix (varenicline) to treat nicotine addiction, had $919 million in 2020 revenues; Inlyta (axitinib), a tyrosine kinase inhibitor to inhibit growth of breast cancer, had $787 million in 2020 revenues; Nimenrix, a meningococcal vaccine, had $221 million in 2020 revenues; FSME/IMMUN-TicoVac, a tick-borne encephalitis vaccine, had $196 million in 2020 revenues; Genotropin, a growth hormone therapy, had $427 million in 2020 revenues; Somavert (pegvisomant), a growth hormone receptor antagonist used in the treatment of acromegaly, had $277 million in 2020 revenues; Toviaz (fesoterodine), an antimuscarinic drug to treat overactive bladders, had $252 million in 2020 revenues; Bone morphogenetic protein 2, had $274 million in 2020 revenues; Sutent (sunitinib), used to treat cancer, had $819 million in 2020 revenues; Xalkori (crizotinib), an anaplastic lymphoma kinase and c-ros oncogene 1 inhibitor for treatment of non-small cell lung carcinoma, had $544 million in 2020 revenues; Bosulif (bosutinib), a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous leukemia, had $450 million in 2020 revenues; Retacrit, an erythropoiesis-stimulating agent, had $386 million in 2020 revenues; Lorbrena (lorlatinib), an anaplastic lymphoma kinase and c-ros oncogene 1 inhibitor used for the treatment of non-small-cell lung cancer, had $204 million in 2020 revenues; Sulperazon (cefoperazone/sulbactam), an antibiotic used for the treatment of urinary tract infections, had $618 million in 2020 revenues; Medrol (methylprednisolone), a glucocorticoid, had $402 million in 2020 revenues; and Vfend (voriconazole), an antifungal medication, had $270 million in 2020 revenues.[1]
П.С. Им се може lycku vis a vis помадата и марамиците на браќава
